- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04235816
Melhorando o atendimento por meio da pesquisa de azitromicina para bebês na África (ICARIA)
Avaliação do impacto na mortalidade infantil de azitromicina mais tratamento preventivo intermitente administrado por meio do programa ampliado de imunização em Serra Leoa
Infectious diseases are among the most common causes of mortality in the over 2.5 million children under 5 years of age (U5) who died in 2018 in sub-Saharan Africa (SSA). New approaches to treatment and prevention of these diseases are needed to increase child survival. Sierra Leone has one of the highest rates of under-five child mortality in the world. It is estimated that 32,000 children die each year, the leading causes being neonatal conditions, malaria, pneumonia and diarrhea. In Sierra Leone, the available information on malaria indicates that it accounts for 38% of deaths among under-five children. Reducing the prevalence and impact of the disease among the general population is a major priority of the Ministry of Health and Sanitation (MoHS) of Sierra Leone .
Intermittent Preventative Treatment in infants (IPTi) - the administration of a full course antimalarial treatment to infants at individual timepoints regardless of infection status- has been shown to reduce clinical malaria and anemia in infants in the first year of life . When delivered alongside the Expanded Program on Immunization (EPI), IPTi with Sulphadoxine-pyrimethamine (SP) is a highly cost-effective intervention. . Sierra Leone is currently the only country that implements nationwide the World Health Organization's (WHO) IPTi guideline, which is administered within the first year of life. However, its benefit when expanded into the second year of life remains unknown. Taking the advantage of the inclusion in the EPI program of a booster dose of measles vaccine at 15 months of age, the ICARIA trial will also assess the efficacy of adding a dose of IPTi-SP at this age.
Recent studies show that azithromycin (AZi) - a macrolide antibiotic with some antimalarial effect- is associated with a significant reduction in childhood mortality when used in mass drug administration (MDA) for trachoma elimination in areas of sub-Saharan Africa (SSA) with child mortality rates far beyond Sustainable Development Goals , . However, despite the potential benefit of the intervention several fundamental scientific questions need to be answered before it can be recommended for large-scale implementation.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
In order to generate the conclusive evidence needed to inform policy and accelerate the implementation of this intervention, we propose to carry out a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through EPI. The potential development of antibiotic and SP resistance, AZi and SP interactions with routine immunizations, as well as the safety and the impact on the health system will be all assessed in the ICARIA trial.
To provide the evidence needed to inform policy and practice and to accelerate the implementation of this intervention, a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through the World Health Organisation Expanded Program on Immunisation (EPI) will be carried out in Sierra Leone. The clinical trial will be individually randomised, placebo-controlled with a factorial design whereby AZi will be administered alongside routine preventive health interventions of the EPI, such as immunisations and Intermittent Preventive Treatment in infants (IPTi), which is recommended by the WHO for malaria prevention in this age group. The potential development of antibiotic resistance, the interactions with routine immunisations, the safety and the impact on the health system of AZi administration will be all assessed in this trial.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Freetown, Serra Leoa
- College of Medicine and Allied Health Sciences
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Parents/guardians have signed the informed consent
- Permanent residence in the study area-health facility catchment area
- Without known allergies to or contraindications to macrolides
- Without known allergies to or contraindications to SP
- Agreement to complete the EPI scheme at the recruitment health facility
- Parents/guardians agree to participate
Exclusion Criteria:
- Residence outside the study area or planning to move out in the following 12 months from enrolment
- Known history of allergy or contraindications to macrolides and/or SP
- Known history of allergy or contraindications to SP
- With signs of any acute illness at the time of recruitment
- Participating in other intervention studies
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Group 1
AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age. |
Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
Outros nomes:
|
|
Comparador de Placebo: Group 2
Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age. |
Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The rate of all-cause mortality
Prazo: 18 months of age
|
all-cause mortality rate at 18 months of age |
18 months of age
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The cause-specific mortality rate
Prazo: 18 months of age
|
Cause-specific mortality rate at 18 months of age |
18 months of age
|
|
Malaria related mortality
Prazo: 18 month of age
|
Malaria related mortality at 18 months of age |
18 month of age
|
|
Incidence of all-cause hospital admissions
Prazo: Through study completion, 36 months
|
Incidence of all-cause hospital admissions |
Through study completion, 36 months
|
|
Incidence of all-cause outpatient attendances
Prazo: Through study completion, 36 months
|
Incidence of all-cause outpatient attendances at the health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (RDT positive) malaria hospital admissions
Prazo: Through study completion, 36 months
|
Incidence of confirmed (RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions
Prazo: Through study completion, 36 months
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Frequency and severity of drug adverse reactions
Prazo: Through study completion, 36 months
|
Frequency and severity of drug adverse reactions throughout the trial |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in nasopharyngeal isolates
Prazo: Through study completion, 36 months
|
Prevalence of macrolide resistance in nasopharyngeal isolates |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in the gut bacteria
Prazo: Through study completion, 36 months
|
Prevalence of macrolide resistance in the gut bacteria |
Through study completion, 36 months
|
|
Proportion of children with protective antibody responses to specific routine EPI immunizations (measles and yellow fever)
Prazo: Through study completion, 36 months
|
Proportion of children with protective antibody responses to specific routine EPI |
Through study completion, 36 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Clara Menendez, MD, PhD, Barcelona Institute for Global Health
Publicações e links úteis
Publicações Gerais
- Chen H, Owusu-Kyei K, Fombah AE, Williams J, Garcia-Fernandez C, Rovira-Vallbona E, Bofill A, Quinto L, Figueroa-Romero A, Mac-Abdul F, Samai M, Mayor A, Menendez C. Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone. Gates Open Res. 2025 Oct 8;9:81. doi: 10.12688/gatesopenres.16367.1. eCollection 2025.
- Owusu-Kyei K, Chen H, Chileshe M, Quinto L, Sibley M, Figueroa-Romero A, Llach M, Ramirez M, Bofill A, Samai M, Menendez C; ICARIA Trial Team. Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA). Trials. 2024 Sep 27;25(1):626. doi: 10.1186/s13063-024-08443-9.
- Chen H, Montero-Vale M, Owusu-Kyei K, Lara-Munoz A, Rubio-Garcia E, de Pedro-Jove R, Guiral E, Chileshe MN, Williams J, Bofill A, Samai M, Casals-Pascual C, Vila J, Menendez C. Early-life carriage and antibiotic resistance of Streptococcus pneumoniae in infants from Sierra Leone. Front Microbiol. 2026 May 22;17:1822296. doi: 10.3389/fmicb.2026.1822296. eCollection 2026.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ICARIA
- OPP1196642 (Número de outro subsídio/financiamento: Bill & Melinda Gates Foundation)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .